Literature DB >> 20304245

Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis.

Jonathan McCormick1, Gita Mehta, Hanne V Olesen, Laura Viviani, Milan Macek, Anil Mehta.   

Abstract

BACKGROUND: Country-specific patients' registries are rarely used to make international comparisons because of protocol discrepancies in data collation. We present data from a European cystic fibrosis registry that is dedicated to collection of demographic data, and assess whether the resources available in countries with and without European Union (EU) membership affects care and survival of patients.
METHODS: Data for demographic indicators-age, age at diagnosis, sex, and genotype-for patients with cystic fibrosis from 35 European countries were combined, and used to establish the differences in demographic indicators between EU and non-EU countries. EU membership status in 2003 was used to divide countries. We modelled demographic indicators of EU countries on non-EU countries to estimate the size of the cystic fibrosis population if non-EU countries had had the same resources available for patients as did EU countries.
FINDINGS: Data were gathered for 29 025 patients, who had a median age of 16.3 years (IQR 8.9-24.8), with a difference of 4.9 years (95% CI 4.4-5.1; p<0.0001) between EU (median 17.0 years, IQR 9.5-25.6) and non-EU countries (12.1 years, 6.0-19.2). The proportion of patients older than 40 years was higher in EU countries (1205 [5%]) than in non-EU countries (76 [2%]), with an odds ratio of 2.4 (95% CI 1.9-3.0, p<0.0001). We estimated that the cystic fibrosis population in non-EU countries would increase by 84% if patients had a demographic profile comparable to that of patients in EU countries.
INTERPRETATION: Future studies need to establish the reasons for the lower proportion of patients with cystic fibrosis in non-EU countries than in EU countries, such as underdiagnosis and premature childhood mortality. FUNDING: European Community's Sixth Framework Programme for Research, and Czech Ministry of Health. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20304245     DOI: 10.1016/S0140-6736(09)62161-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

1.  Children and young adults with CF in the USA have better lung function compared with the UK.

Authors:  Christopher H Goss; Stephanie J MacNeill; Hebe B Quinton; Bruce C Marshall; Alexander Elbert; Emily A Knapp; Kristofer Petren; Elaine Gunn; Joanne Osmond; Diana Bilton
Journal:  Thorax       Date:  2014-09-25       Impact factor: 9.139

2.  HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain.

Authors:  L Gulácsi; M Péntek
Journal:  Eur J Health Econ       Date:  2014-09

3.  Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.

Authors:  Tomáš Mlčoch; Jiří Klimeš; Libor Fila; Věra Vávrová; Veronika Skalická; Marek Turnovec; Veronika Krulišová; Jitka Jirčíková; Dana Zemková; Klára Vilimovská Dědečková; Alena Bílková; Vladimíra Frühaufová; Lukáš Homola; Zuzana Friedmannová; Radovan Drnek; Pavel Dřevínek; Tomáš Doležal; Milan Macek
Journal:  Eur J Health Econ       Date:  2016-01-07

Review 4.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

5.  Probiotics for people with cystic fibrosis.

Authors:  Michael J Coffey; Millie Garg; Nusrat Homaira; Adam Jaffe; Chee Y Ooi
Journal:  Cochrane Database Syst Rev       Date:  2020-01-22

Review 6.  Cystic fibrosis related diabetes.

Authors:  Donal O'Shea; Jean O'Connell
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

7.  BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.

Authors:  Gerd Döring; Alessandra Bragonzi; Moira Paroni; Firdevs-Fatma Aktürk; Cristina Cigana; Annika Schmidt; Deirdre Gilpin; Susanne Heyder; Torsten Born; Christina Smaczny; Martin Kohlhäufl; Thomas O F Wagner; Michael R Loebinger; Diana Bilton; Michael M Tunney; J Stuart Elborn; Gerald B Pier; Michael W Konstan; Martina Ulrich
Journal:  J Cyst Fibros       Date:  2013-10-31       Impact factor: 5.482

Review 8.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

9.  Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study.

Authors:  Anne L Stephenson; Jenna Sykes; Sanja Stanojevic; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza K Fink; Alexander Elbert; Christopher H Goss
Journal:  Ann Intern Med       Date:  2017-03-14       Impact factor: 25.391

Review 10.  RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research.

Authors:  Rachel Thompson; Louise Johnston; Domenica Taruscio; Lucia Monaco; Christophe Béroud; Ivo G Gut; Mats G Hansson; Peter-Bram A 't Hoen; George P Patrinos; Hugh Dawkins; Monica Ensini; Kurt Zatloukal; David Koubi; Emma Heslop; Justin E Paschall; Manuel Posada; Peter N Robinson; Kate Bushby; Hanns Lochmüller
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.